HCmed Innovations Co., Ltd. (HCmed) is honored to be listed as one the winners awarded for its growth potential.

HCmed Innovations is delighted to announce that it has received US Food and Drug Administration (FDA) 510(k) clearance for its portable mesh nebulizer, Pulmogine.

HCmed Innovations (HCmed) signed an agreement with Cathay Securities on June 21st, 2021, to prepare for its initial public offering (IPO).

Companies Initiated Phase I trial in December 2020

In its second consecutive year showcasing as an invited guest of I-Campus at the CIIE, HCmed Innovations was delighted to introduce its new smart device prototype

We are delighted to announce that SinoMedCare BioTech Co., Ltd. (SMC) has become the exclusive distributor of our vibrating mesh nebulizer Pulmogine in China.

HCmed is ready to join the fight. Our mesh nebulizers are highly efficient customizable devices that deliver drugs deep into the lungs.

HCmed Innovations is pleased to inform that it has received NMPA approval from the National Medical Products Administration in China for its handheld mesh nebulizer, Pulmogine.

HCmed Innovations is pleased to inform that it has received NMPA approval from the National Medical Products Administration in China for its handheld mesh nebulizer, Pulmogine.